Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:THRX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $9.81
- 200 Day Moving Avg: $11.67
- 52 Week Range: $6.36 - $21.16
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 32.70
- P/E Growth: 0.00
- Average Volume: 867,484 shs.
Frequently Asked Questions for Innoviva (NASDAQ:THRX)
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "THRX."
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Orange Belgium (MBSRF), Abengoa SA (ABGB), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Facebook (FB), Premier Foods Spon (PRRFY), Berkshire Hathaway (BRK-A), Nestle SA (NSRGY), Roche Holding (RHHBY), RDS-A (RDS-A), Comcast (CMCSA), Intel (INTC), Cisco Systems (CSCO), LVMH Moet Hennessy Louis Vuitton SE (LVMUY) and Inditex (IDEXY).
How do I buy Innoviva stock?
Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Innoviva stock cost?
One share of Innoviva stock can currently be purchased for approximately $9.81.
Consensus Ratings for Innoviva (NASDAQ:THRX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Innoviva (NASDAQ:THRX)
(Data available from 5/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/2/2016||Morgan Stanley||Reiterated Rating||Sell||$7.00||N/A|
Earnings History for Innoviva (NASDAQ:THRX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Innoviva (NASDAQ:THRX)
Current Year EPS Consensus Estimate: $-0.19 EPS
Next Year EPS Consensus Estimate: $0.30 EPS
Dividend History for Innoviva (NASDAQ:THRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Innoviva (NASDAQ:THRX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Innoviva (NASDAQ:THRX)
Latest Headlines for Innoviva (NASDAQ:THRX)
Innoviva (THRX) Chart for Friday, May, 26, 2017